Healthcare [ 11/13 ] | Biotechnology [ 98/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 0 Increased by +100% | -0.26 Increased by +100% |
| Mar 26, 24 | -0.28 Increased by +12.5% | -0.26 Decreased by -7.69% |
| Nov 13, 23 | -0.24 Increased by +7.69% | -0.27 Increased by +11.11% |
| Aug 8, 23 | -0.28 Decreased by -12% | -0.35 Increased by +20% |
| May 9, 23 | -0.28 Decreased by -21.74% | -0.35 Increased by +20% |
| Mar 27, 23 | -0.32 Increased by +23.81% | -0.25 Decreased by -28% |
| Nov 14, 22 | -0.26 Decreased by -160% | -0.23 Decreased by -13.04% |
| Aug 15, 22 | -0.25 Increased by +96.84% | -0.24 Decreased by -4.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -12.96 M Decreased by -28.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -11.61 M Decreased by -17.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -9.48 M Decreased by -4.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -13.86 M Decreased by -66.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -10.05 M Decreased by -157.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -9.89 M Increased by +83.88% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -9.05 M Increased by +66.47% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by -100% | -8.35 M Decreased by -1.01 K% | Decreased by N/A% Decreased by N/A% |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.